Premium
Investigating the Effects of 12 Week Almond Consumption in Type 2 Diabetes.
Author(s) -
Ricklefs Kristin,
Petersen Katherine,
Alanbagy Sameer,
Johnston Carol S,
Sweazea Karen L
Publication year - 2013
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.27.1_supplement.lb424
Subject(s) - medicine , type 2 diabetes , diabetes mellitus , waist , blood pressure , randomized controlled trial , stroke (engine) , clinical endpoint , body mass index , endocrinology , mechanical engineering , engineering
The national cost of diabetes exceeds $174 billion each year. Heart disease and stroke are the primary causes of death and disability among people with type 2 diabetes (T2D). The objective of this ongoing 12‐week randomized, parallel‐arm controlled feeding trial is to determine if the addition of almonds (1.5 oz/d) to a normal diet will result in significant improvements in diabetic and cardiovascular risk markers in subjects with T2D who are not currently taking insulin compared to matched controls who were instructed to maintain their normal eating patterns. To date, twelve participants have completed the trial (5 almond and 7 controls). Although the change in biomarkers are not significantly different between groups at this point in the trial, change in biomarkers were favorable for the almond vs. controls for hemoglobin A1c (−2% vs. +1%), diastolic blood pressure (−6% vs. 0), and waist circumference (−3% vs. +1%). Enrollment continues in the trial through March 2013. Previous studies from our labs have shown almonds to promote a significant reduction in hemoglobin A1c and improvements in anthropometric indices in individuals with T2D. This trial will provide further evidence regarding the efficacy of daily almond ingestion for managing the diabetic condition. This study was funded by The Almond Board of California.